Clinical Research
Cancer clinical trials are at the heart of all treatment advances and are key to developing new methods to prevent, detect, and treat cancer. It is through clinical studies that researchers can determine whether new treatments are safe, effective, and if they work better than what is currently available to patients. When you take part in a clinical trial, you add to knowledge about cancer and help improve cancer care for yourself and others.
The Bassett Cancer Institute has been providing access to cutting edge treatments in a convenient, local setting for over 40 years. Bassett Healthcare Network's membership in the Eastern Cooperative Oncology Group (ECOG) allows access to numerous clinical trials through the Clinical Trials Support Unit (CTSU), funded by The National Institutes of Health (NIH) and The National Cancer Institutes (NCI).
Why Should I Consider a Clinical Trial?
Clinical trials are voluntary. Participants receive high-quality care that experts believe may have the potential to become a new standard of cancer treatment. Treatments might be new drugs or new combinations of drugs, new devices, or new ways to use existing treatments. When patients participate in a clinical trial, they are contributing to research that could bring new treatments one step closer to reaching patients across the nation.
ACT (About Clinical Trials) is a great resource for patients considering participation in a clinical trial. The experts and participants in these videos help educate about clinical trials, including what questions to ask about available treatment options, what to consider before participating in a trial, and how to know if a particular trial may be a good option for you.
If you are interested in more information about clinical trials, please call the Bassett Medical Center Clinical Trials office at 1-(877)-547-1750.
Cancer Clinical Trials at Bassett Healthcare Network
Available Clinical Studies
Learn more about our current clinical studies:
CTP-SCC-03
A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma.
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT05323253
(Project 1954534)
Timothy Korytko, M.D.
EA2182
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE).
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT04166318
(Project 1569042)
Timothy Korytko, M.D.
CCTG MA.39
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03488693
(Project 1525614)
Julia Manzerova, M.D.
S1703
A Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Markers Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03723928
(Project 1350363)
Eric Bravin, M.D.
NRG-BR007
A Phase III Clinical Trial Evaluating Deescalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ≤ 18 Breast Cancer
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT04852887
(Project 1838252)
Timothy Korytko, M.D.
A221805
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT04137107
(Project 1613205)
Eric Bravin, M.D.
A031704
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03793166
(Project 1442850)
Eric Bravin, M.D.
LUNGMAP
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03851445
(Project 1368750)
Eric Bravin, M.D.
S1900E
A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT04625647
(Project 1745730)
Eric Bravin, M.D.
S1900F
A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT05364645
(Project 1952006)
Eric Bravin, M.D.
S1914
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT04214262
(Project 1968226)
Eric Bravin, M.D.
A151216
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02194738
(Project 1246946)
Eric Bravin, M.D.
E4512
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02201992
(Project 1246948)
Eric Bravin, M.D.
A081801
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT04267848
(Project 1627574)
Eric Bravin, M.D.
CTP-SCC-03
A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients with Recurrent Cutaneous Squamous Cell Carcinoma
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT05323253
(Project 1954534)
Timothy Korytko, M.D.
EA6141
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma (Temporarily closed to accrual)
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02339571
(Project 1246966)
Eric Bravin, M.D.
Call or Email to Learn More About Participating in a Clinical Trial
Call our specialists at 1-877-547-1750, or email us at cancerclinicaltrials@bassett.org to learn more about participating in a cancer clinical trial.
Bassett Healthcare Network’s Cancer Treatment Center offers Cancer Clinical Trials in Central New York, including Cooperstown, Oneonta, Cobleskill, and Herkimer.
